000 01297 a2200325 4500
005 20250517132729.0
264 0 _c20180223
008 201802s 0 0 eng d
022 _a1552-4604
024 7 _a10.1002/jcph.858
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aFreise, Kevin J
245 0 0 _aQuantitative Prediction of the Effect of CYP3A Inhibitors and Inducers on Venetoclax Pharmacokinetics Using a Physiologically Based Pharmacokinetic Model.
_h[electronic resource]
260 _bJournal of clinical pharmacology
_c06 2017
300 _a796-804 p.
_bdigital
500 _aPublication Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
650 0 4 _aAntineoplastic Agents
_xblood
650 0 4 _aBridged Bicyclo Compounds, Heterocyclic
_xblood
650 0 4 _aCytochrome P-450 CYP3A Inducers
_xpharmacology
650 0 4 _aCytochrome P-450 CYP3A Inhibitors
_xpharmacology
650 0 4 _aDrug Interactions
650 0 4 _aFemale
650 0 4 _aHumans
650 0 4 _aModels, Biological
650 0 4 _aSulfonamides
_xblood
700 1 _aShebley, Mohamad
700 1 _aSalem, Ahmed Hamed
773 0 _tJournal of clinical pharmacology
_gvol. 57
_gno. 6
_gp. 796-804
856 4 0 _uhttps://doi.org/10.1002/jcph.858
_zAvailable from publisher's website
999 _c26752409
_d26752409